NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 56.8% from a year ago
Total assets stood at $11.9M at the end of Q1 FY2026, up 56.8% from a year earlier and down 8.1% from the prior quarter. Over 3 fiscal years it compounded at -20.5% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +56.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 12.96M USD
- Year-over-year change
- +254.9%
- 4-year CAGR
- -20.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.96M | +254.9% |
| FY2024 | 2024-12-31 | 3.65M | -50.1% |
| FY2023 | 2023-12-31 | 7.32M | -71.7% |
| FY2022 | 2022-12-31 | 25.82M | -21.1% |
| FY2021 | 2021-12-31 | 32.73M | — |
Total Assets vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total assets of $11.9M is the lowest of the 9 companies compared; the peer median is $43.52M.
- Its year-over-year change of +56.8% is the 3rd highest of 9, against a peer median of +26.8%.
- Over three fiscal years its annual growth of -20.5% compares with a peer median of -22.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $326.55M | +3.5% | -22.8% | |
| Mar 2026 | $131.42M | +2.9% | -32.9% | |
| Mar 2026 | $63.08M | +277.1% | -25.9% | |
| Mar 2026 | $56.17M | +77.5% | -14.8% | |
| Mar 2026 | $30.88M | +38.7% | -22.7% | |
| Jun 2026 | $24.16M | -73.9% | -24.3% | |
| Mar 2026 | $21.89M | +14.8% | -13.3% | |
| Mar 2026 | $19.79M | +47.1% | +35.8% | |
| Mar 2026 | $11.9M | +56.8% | -20.5% | |
| Peer median (excluding NRXP) | $43.52M | +26.8% | -22.7% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.